Alvorlige bivirkninger forekom hos. 2, 4% af patienterne i Keppragruppen og 2, 0% af patienterne i placebogruppen.
Serious undesirable effects were experienced in 2.4% of the patients in the Keppra and 2.0% of the patients in the placebo groups.